Positive pre-clinical data sends Prana Technology shares soaring

(Before It's News)

Shares in Prana Biotechnology Ltd (NASDAQ: PRAN) raced up over 44% today as it unveiled positive pre-clinical data about its PBT434 therapy for treating movement disorders in Parkinson’s disease.

Shares added  44.35% to stand at $3.58 each.

The firm will present what’s called a poster showing in vivo (in living organisms) evidence of the ability of PBT434 to prevent the loss of neurons that underpin motor and cognitive dysfunction.

For example, PBT434 intervenes in the production of damaging reactive oxygen species that are toxic to normal cell function and the compound also prevents the accumulation of misfolded forms of the tau protein, which are known to promote cell death, the company said.

The poster will be featured at the 13th international conference for Alzheimer’s and Parkinson’s Diseases in Vienna from  March 29 to 2 April 2017.

Story by ProactiveInvestors

• How To Play The Gap Up Fade
• Sienna Resources ends 2016 with $18,618 in cash
• Head of ETF Strategy at John Hancock Shares Views on Market Trends
• Premier Holding’s new tie-up with AER Lighting to expand sales in Midwest
• Sponsored: 64% off Code Black Drone with HD Camera [del.icio.us]
• Short Selling of Banks Accelerates as New Financial Stress Test [del.icio.us]
• Second Look at the Federal Reserve by Edward Griffin 1 of 7 [del.icio.us]
• Free Educational Stock Market Videos – Hamzei Analytics [del.icio.us]
• Loss of Biodiversity and Extinctions — Global Issues [del.icio.us]
• The man who planted trees [del.icio.us]